Stifel Financial Corp Sells 530 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Stifel Financial Corp lowered its stake in Royalty Pharma plc (NASDAQ:RPRX) by 2.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,352 shares of the biopharmaceutical company’s stock after selling 530 shares during the period. Stifel Financial Corp’s holdings in Royalty Pharma were worth $547,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its holdings in shares of Royalty Pharma by 362.7% during the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 943 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Royalty Pharma by 32.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 655 shares in the last quarter. Transamerica Financial Advisors Inc. raised its holdings in Royalty Pharma by 99.9% in the third quarter. Transamerica Financial Advisors Inc. now owns 3,459 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,729 shares during the last quarter. iA Global Asset Management Inc. lifted its stake in shares of Royalty Pharma by 274.7% in the second quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 4,683 shares in the last quarter. Finally, Lake Street Advisors Group LLC purchased a new stake in shares of Royalty Pharma during the third quarter valued at approximately $211,000. Institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Citigroup decreased their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, October 25th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research note on Tuesday. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma currently has a consensus rating of “Buy” and an average target price of $41.67.

Royalty Pharma Price Performance

Shares of RPRX opened at $25.40 on Friday. The firm has a fifty day simple moving average of $26.21 and a two-hundred day simple moving average of $27.10. The firm has a market cap of $14.97 billion, a PE ratio of 13.16, a P/E/G ratio of 4.36 and a beta of 0.46. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $31.66.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date of this dividend was Friday, November 15th. Royalty Pharma’s dividend payout ratio is 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.